Table 1 Study characteristics
Author and year | Study design | Sample size | Study region (state and region) | Age of study participants (and mean age) | Gender | Prevalence | Treatment used | Treatment regimen | Clinical outcomes |
|---|---|---|---|---|---|---|---|---|---|
Runsewe-Abiodun, I.T. et al. 2006 | Retrospective descriptive study | 230 | Sagamu, Ogun state | 1–7 days (6.7 days) | M-35, F-22 M:F—1.6:1 | 57 (17.4%) | Chloroquine in 50 | Sulf- adoxine-Pyrimethamine (SP) in 1 6 received no treatment | 42 responded to treatment and were subsequently discharged home, 4 died and 11 DAMA |
Falade C. et al. 2007 | Prospective, descriptive study | 1875 (625 from each region) | 3 Nigerian geopolitical zones (Oyo, Kwara, and kaduna states) | 0–7 days | Not provided | 95 (5.1%) | CQ used for babies who were symptomatic before day 3 or who had persistent parasitemia | SP used those who failed to show response to CQ by day 3 | Good clinical improvement with Chloroquine in symptomatic and asymptomatic babies (88.4% parasitological cure at day 14). 4 who failed to respond to CQ achieved cure with oral SP |
Obiajunwa PO. et al. 2005 | Retrospective descriptive study | 120 | Ile-Ife, Osun State | 1–7 day | M-54, F-66 | 56 (46.7%) | CQ given to 46 parasitaemic babies. 10 were not treated and followed up to age 6 weeks | No other regimen used | Babies treated with CQ showed good responses. 10 who were not treated had no clinical manifestations at follow-up |
M. Y. Mukhtar et al. 2005 | Prospective, descriptive study | 104 | Lagos state | 1–7 days | Not provided | 14 (13.4%) | No medication was administered and babies were followed up till 28 days |  | On days 3, 7, 14, and 28, only 10, 8, 7 and 1 were still parasitemic, respectively |
A.A Okechukwu et al. 2011 | Prospective, descriptive study | 266 | Abuja, FCT | 5.1 ± 2.3 days | M-35, F-41 M:F-0.9:1 | 76 (28.6%) | All neonates with moderate and high MP density were treated with Oral Quinine |  | Good clinical outcomes noticed days after treatment |
Bo Onankpa et al. 2007 | Descriptive study | 162 | Sokoto | Aged < 8 days | M-82, F-74 M:F-1.2:1 | 156 (96.3%) |  | Artemether-lumefantrine | The efficacy of artemether-lumefantrine was significant in treating those with parasitemia |
Anyanwu E. B. et al. 2008 | Case report | 3 | Eku, Delta state | 2–6 days | M-2, F-1 | 75% | 1st baby–Quinine infusion 2nd and 3rd babies—Oral quinine suspension |  | The 3 babies tolerated and responded well to Quinine |
Okonkwo Victor et al. 2022 | Descriptive study | 200 | Awka, Anambra state | 1–7 days (6.8 days) | M-108, F-92 M:F-1.2:1 | 74 (37%) | Amodiaquine and/or chloroquine | Sulfadoxine-pyrimethamine | Following treatment, significant of the babies showed good clinical response and subsequently discharged |
Hyacinth HI. et al. 2012 | Prospective descriptive study | 41 | Jos, Plateau state | 1–7 days | M-12, F-12 M:F-1:1 | 24 (58.5%) | Amodiaquine in 20 Quinine in 3 | Amodiaquine + quinine in 1 | 18 (75%) were discharged alive while 6 (25%) died |
Diala, U.M. et al. 2017 | Prospective descriptive study | 301 | Jos, Plateau state | 0–7 days (4.4 days) | M-193, F-108 M:F-1.8:1 | 16 (5.3%) | Amodiaquine administered in all Quinine was given to one |  | 15 (94%) attained clinical and parasitological cure with Amodiaquine only while 1 required retreatment with quinine |
A. A. Orogade 2004 | Descriptive study | 206 | Zaria, Kaduna state | 1–7 days | M-9, F-8 | 17 (8.25%) | All 17 were treated with CQ (Initial subcutaneous dose and followed by daily oral doses for 2 days) |  | 100% fever clearance rate by end of 2nd days’ dose and 100% parasite clearance at the end of therapy |
Nwaneli EI. et al. 2022 | Case report | 1 | Anambra | 5Â day | M | Â | Intravenous Artesunate (5 doses at 3Â mg/kg) | Oral Artesunate-Amodiaquine was commenced for 3Â days after the 5th of IV artesunate | Consciousness improved gradually after the commencement of IV artesunate |